« Previous | Next » | All Messages |  PBME Message Board Home | recommend post |  Ignore Poster

PBME News Pacific Biometrics' Chief Medical Officer Dr. Mario Ehlers to Present at the Partnering with Central Labs, ECG, and Imaging Labs Conference, January 17-19 in Anaheim, CA

SEATTLE--(BUSINESS WIRE)--Mario Ehlers, M.D., Ph.D., the Chief Medical Officer of Pacific Biometrics, Inc. (OTCBB:PBME) ("PBI"), will present at the 5^th annual Partnering with Central Labs, ECG, and Imaging Labs conference. The conference takes place January 17-19 and will be held at the Disneyland Hotel in Anaheim, CA. Dr. Ehlers will talk on “Use of Biochemical and Imaging Biomarkers in the Clinical Development of Lipid-modifying Drugs” in a workshop entitled “Overcoming Operational Challenges in Implementing Biomarkers in Clinical Trials.” His co-presenter will be David S. Lester, Ph.D., New York Site Head, Human Health Technologies, Pfizer Global Research and Development.

The Partnering with Central Labs, ECG, and Imaging Labs conference is the only conference focused on aligning sponsors and labs globally, and brings small and large sponsors and lab partners together to build more efficient processes from the initial selection process through final database lock.

"Outsourcing is a critical component of pharmaceutical and biotech R&D activities. At PBI we have provided laboratory testing in support of clinical drug development for many of the world’s largest pharma companies for the past 17 years. We have built a strong reputation in our focus areas, including cardiovascular, metabolic, and lipid disorders," commented Dr. Ehlers. "More and more emphasis is being placed on the use of biomarkers to facilitate drug development, and we are honored to present on the use of biomarkers in the field of lipid drugs at this key industry conference. Expertise in biomarkers is increasingly required in the evolving drug-development paradigm.”

For more information about the conference, please visit www.partneringwithlabs.com.

About Pacific Biometrics, Inc.

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information, visit the Company Web site at www.pacbio.com.